ANTI-HIV DRUGS IN CLINICAL TRIALS
DrugManufacturerTargetStageAttributes
T-20Trimeris/Hoffmann-La RocheEntry (gp41)Phase IIINovel target
atazanavirBristol-Myers SquibbProteasePhase IIILow lipid tox., 1 pill/day
FTC (emtricitabine)Triangle PharmaceuticalsRTPhase III1 pill/day
tipranavirBoehringer IngelheimProteasePhase II/IIIResistance
DPC-083Bristol-Myers SquibbRTPhase IIResistance
DAPDTriangle PharmaceuticalsRTPhase I/IIResistance
T-1249TrimerisEntry (gp41)Phase I/IINovel target
TMC 125Tibotec-VircoRTPhase IUltrapotent
L-870,810Merck & Co. Inc.IntegrasePhase INovel target
S-1360Shionogi/GlaxoSmithKlineIntegrasePhase INovel target
SCH-CSchering-PloughEntry (CCR5)Phase INovel target
BMS-806Bristol-Myers SquibbEntry (gp120/CD4)Phase IEarliest entry stage
  • SOURCES: COMPANIES, AMFAR, TREATMENT NEWS